Keywords
How to Cite
Abstract
Aim: To identify incidence and prognostic impact of different IHC and molecular genetic markers in Diffuse Large B-cell lymphoma. Methods: We analyzed 215 patients with DLBCL who received treatment from 2008 to 2016. We assess expression of different IHC markers, defined DLBCL to GCB and non-GCB subtypes by Hans-algorithm and performed FISH to evaluate MyC, BcL2 and BCL6 translocations. Results: Median follow-up was 29 months. Non-GCB DLBCL were identified in 44 pts (62,9%), GCB-subtype in 26 pts (37,1%). Median PFS in non-GCB DlBCL was 46,0 months, in GCB DLBCL median PFS and 75% quartile was not reached (p=0,171). Traslocations of MYC, BCL2 and BCL6 were found in 10/48 pts (20,8%). Double expression of c-myc and bcl-2 was identified in 21 of 71 пациентов (29,6%). СD5-expression were determined in 19/55 (34,5%), CD30+ DLBCL - in 24/66 pts (36,4%). In pts with DLBCL without CD-10 expression PFS was 6,0 months, in group with CD 10 expression median of PFS was not reached (р=0,122). Pts with CD 10 expression had lower risk of relapse compared to those without expression (р=0,049). Absence of CD 10 expression was negative prognostic factor for PFS in multivariate analysis (р=0,015). Conclusion: Patients with DLBCL and GCB subtype have tendency to better prognosis in PFS rates and lower risk of relapse compared to non-GCB subtype. Dividing to GCB or non-GCB subtypes in DLBCL and assessment of different IHC markers can potentially determine DLBCL with worse prognosis.
References
Tilly H., Gomes da Silva M., Vitolo U. et al. Diffuse Large B-Cell Lymphoma: ESMO Clinical Practice Guidelines // Ann Oncol. - 2015. - Vol. 26 (suppl 5). - P. v116-v125.
Cohen J.B. Novel therapies for relapsed/refractory aggressive lymphomas // Hematology Am Soc Hematol Educ Program. - 2018. - Vol. 2018(1). - P. 75-82.
Swerdlow S.H., Campo E., Harris N.L. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. - Lyon: International Agency for Research on Cancer (IARC), 2016.
Schmidt-Hansen M., Berendse S., Marafioti T., McNamara C. Does cell-oforigin or MYC, BCL2 or PCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review // Leuk Lymphoma. -2017. - Vol. 58. - P. 2403-2418.
Batlle-Lopez A., Gonzalez de Villambrosia S., Francisco M. et al. Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker // Oncotarget. - 2016. - Vol. 7 (14). - pp. 18036-18049.
Oki Y, Noorani M., Lin P. et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience // Br. J. Haematol. - 2014. - Vol. 166. - P. 891-901.
Shimin Hu., Zijun Y Xu-Monette, Alexander Tzankov et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program // Blood. -2013. - Vol. 121(20). - P. 4021-4031.
Поддубная И.В., Савченко В.Т. и соавт. Российские Клинические Рекомендации по диагностике и лечению лимфопролиферативных заболеваний // Современная Онкология. - 2014. - C. 9-10.
Руководство по иммуногистохимической диагностике опухолей человека 4-е изд., доп. и перераб / Под ред. С.В. Петрова, Т.Н. Райхлина-Казань, 2012. - С. 312-338.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2020